Induction of heme oxygenase-1 (HO-1) and NAD[P]H: Quinone oxidoreductase 1 (NQO1) by a phenolic antioxidant, butylated hydroxyanisole (BHA) and its metabolite, tert-butylhydroquinone (tBHQ) in primary-cultured human and rat hepatocytes

Pharmaceutical Research

Volumn 23, Issue 11, 2006, Pages 2586-2594

  Keum, Young Sam ^a   Han, Yong Hae ^b   Liew, Celine ^c   Kim, Jung Hwan ^a   Xu, Changjiang ^a   Yuan, Xiaoling ^a   Shakarjian, Michael P ^d   Chong, Saeho ^b   Kong, Ah Ng ^a  

^a RUTGERS UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Butylated hydroxyanisole (BHA); Mitogen activated protein kinases (MAPKs); Nrf2; tert butylhydroquinone (tBHQ)

Indexed keywords

BUTYLATED HYDROXYANISOLE; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; OXIDOREDUCTASE; QUINONE OXIDOREDUCTASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STRESS ACTIVATED PROTEIN KINASE; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; LIVER CELL CULTURE; MICROARRAY ANALYSIS; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; ANTIOXIDANTS; BUTYLATED HYDROXYANISOLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INDUCTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEME OXYGENASE-1; HEPATOCYTES; HUMANS; HYDROQUINONES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; MICE, INBRED C57BL; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33750625742     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9094-2     Document Type: Article

References (40)

1. J. S. Lee and Y. J. Surh. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 224:171-184 (2005).
2. C. Chen and A. N. Kong. Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic. Biol. Med. 36:1505-1516 (2004).
3. K. Itoh, T. Chiba, S. Takahashi, T. Ishii, K. Igarashi, Y. Katoh, T. Oyake, N. Hayashi, K. Satoh, I. Hatayama, M. Yamamoto, and Y. Nabeshima. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 236:313-322 (1997).
4. Y. J. Surh. Cancer chemoprevention with dietary phytochemicals. Nat. Rev., Cancer 3:768-780 (2003).
5. L. E. Otterbein, M. P. Soares, K. Yamashita, and F. H. Bach. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol. 24:449-455 (2003).
6. K. A. Kirkby and C. A. Adin. Products of heme oxygenase and their potential therapeutic applications. Am. J. Physiol., Renal Physiol. 290:F563-F571 (2006).
7. Z. Dong, Y. Lavrovsky, M. A. Venkatachalam, and A. K. Roy. Heme oxygenase-1 in tissue pathology: the yin and yang. Am. J. Pathol. 156:1485-1488 (2000).
8. D. E. Baranano, M. Rao, C. D. Ferris, and S. H. Snyder. Biliverdin reductase: a major physiologic cytoprotectant. Proc. Natl. Acad. Sci. USA 99:16093-16098 (2002).
9. L. E. Otterbein, F. H. Bach, J. Alam, M. Soares, H. Tao Lu, M. Wysk, R. J. Davis, R. A. Flavell, and A. M. Choi. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6:422-428 (2000).
10. R. Foresti, J. Hammad, J. E. Clark, T. R. Johnson, B. E. Mann, A. Friebe, C. J. Green, and R. Motterlini. Vasoactive properties of CORM-3, a novel water-soluble carbon monoxide-releasing molecule. Br. J. Pharmacol. 142:453-460 (2004).
11. H. O. Pae, G. S. Oh, B. M. Choi, S. C. Chae, Y. M. Kim, K. R. Chung, and H. T. Chung. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. J. Immunol. 172:4744-4751 (2004).
12. B. S. Zuckerbraun, T. R. Billiar, S. L. Otterbein, P. K. Kim, F. Liu, A. M. Choi, F. H. Bach, and L. E. Otterbein. Carbon monoxide protects against liver failure through nitric oxide-induced heme oxygenase 1. J. Exp. Med. 198:1707-1716 (2003).
13. C. D. Ferris, S. R. Jaffrey, A. Sawa, M. Takahashi, S. D. Brady, R. K. Barrow, S. A. Tysoe, H. Wolosker, D. E. Baranano, S. Dore, K. D. Poss, and S. H. Snyder. Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat. Cell Biol. 1:152-157 (1999).
14. P. Nioi and J. D. Hayes. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555:149-171 (2004).
15. D. Ross. Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 36:639-654 (2004).
16. G. Asher, J. Lotem, B. Cohen, L. Sachs, and Y. Shaul. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. USA 98:1188-1193 (2001).
17. G. Asher, J. Lotem, L. Sachs, C. Kahana, and Y. Shaul. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. USA 99:13125-13130 (2002).
18. L. W. Wattenberg. Inhibition of chemical carcinogen-induced pulmonary neoplasia by butylated hydroxyanisole. J. Natl. Cancer Inst. 50:1541-1544 (1973).
19. B. S. Reddy, Y. Maeura, and J. H. Weisburger. Effect of various levels of dietary butylated hydroxyanisole on methylazoxymethanol acetate-induced colon carcinogenesis in CF1 mice. J. Natl. Cancer Inst. 71:1299-1305 (1983).
20. F. L. Chung, M. Wang, S. G. Carmella, and S. S. Hecht. Effects of butylated hydroxyanisole on the tumorigenicity and metabolism of N-nitrosodimethylamine and N-nitrosopyrrolidine in A/J mice. Cancer Res. 46:165-168 (1986).
21. G. M. Williams and M. J. Iatropoulos. Inhibition of the hepatocarcinogenicity of aflatoxin B1 in rats by low levels of the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene. Cancer Lett. 104:49-53 (1996).
22. H. Verhagen, P. A. Schilderman, and J. C. Kleinjans. Butylated hydroxyanisole in perspective. Chem. Biol. Interact. 80:109-134 (1991).
23. H. Verhagen, H. H. Thijssen, F. ten Hoor, and J. C. Kleinjans. Disposition of single oral doses of butylated hydroxyanisole in man and rat. Food Chem. Toxicol. 27:151-158 (1989).
24. L. W. Wattenberg, J. B. Coccia, and L. K. Lam. Inhibitory effects of phenolic compounds on benzo(a)pyrene-induced neoplasia. Cancer Res. 40:2820-2823 (1980).
25. B. Hager, J. R. Bickenbach, and P. Fleckman. Long-term culture of murine epidermal keratinocytes. J. Invest. Dermatol. 112:971-976 (1999).
26. G. Shen, C. Xu, R. Hu, M. R. Jain, S. Nair, W. Lin, C. S. Yang, J. Y. Chan, and A. N. Kong. Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm. Res. 22:1805-1820 (2005).
27. D. Stewart, E. Killeen, R. Naquin, S. Alam, and J. Alam. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J. Biol. Chem. 278:2396-2402 (2003).
28. J. Alam, E. Killeen, P. Gong, R. Naquin, B. Hu, D. Stewart, J. R. Ingelfinger, and K. A. Nath. Heme activates the heme oxygenase-1 gene in renal epithelial cells by stabilizing Nrf2. Am. J. Physiol. Renal Physiol. 284:F743-F752 (2003).
29. Y. S. Keum, W. S. Jeong, and A. N. Kong. Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms. Mutat. Res. 555:191-202 (2004).
30. D. Ross, J. K. Kepa, S. L. Winski, H. D. Beall, A. Anwar, and D. Siegel. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129:77-97 (2000).
31. W. S. Jeong, M. Jun, and A. N. Kong. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox Signal. 8:99-106 (2006).
32. S. R. Chinni and F. H. Sarkar. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells. Clin. Cancer Res. 8:1228-1236 (2002).
33. M. Saleem, F. Afaq, V. M. Adhami, and H. Mukhtar. Lupeol modulates NF-kappaB and PI3K/Akt pathways and inhibits skin cancer in CD-1 mice. Oncogene 23:5203-5214 (2004).
34. K. H. Chun, J. W. Kosmeder II, S. Sun, J. M. Pezzuto, R. Lotan, W. K. Hong, and H. Y. Lee. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. 95:291-302 (2003).
35. R. Kahl, S. Weinke, and H. Kappus. Production of reactive oxygen species due to metabolic activation of butylated hydroxyanisole. Toxicology 59:179-194 (1989).
36. P. A. Schilderman, J. M. van Maanen, E. J. Smeets, F. ten Hoor, and J. C. Kleinjans. Oxygen radical formation during prostaglandin H synthase-mediated biotransformation of butylated hydroxyanisole. Carcinogenesis 14:347-353 (1993).
37. D. C. Thompson, Y. N. Cha, and M. A. Trush. The peroxidase-dependent activation of butylated hydroxyanisole and butylated hydroxytoluene (BHT) to reactive intermediates. Formation of BHT-quinone methide via a chemical-chemical interaction. J. Biol. Chem. 264:3957-3965 (1989).
38. G. M. Williams, M. J. Iatropoulos, and J. Whysner. Safety assessment of butylated hydroxyanisole and butylated hydroxytoluene as antioxidant food additives. Food Chem. Toxicol. 37:1027-1038 (1999).
39. F. Iverson. In vivo studies on butylated hydroxyanisole. Food Chem. Toxicol. 37:993-997 (1999).
40. R. Yu, S. Mandlekar, and A. T. Kong. Molecular mechanisms of butylated hydroxylanisole-induced toxicity: induction of apoptosis through direct release of cytochrome c. Mol. Pharmacol. 58:431-437 (2000).